

## Table of Contents

<b>Chapter 1</b>	General Introduction and Outline of the Thesis	<b>7</b>
<b>Chapter 2</b>	Effect on Glycemic Control of Synthetic Exendin-4 (AC2993) Additive to Existing Metformin and/or Sulfonylurea Treatment in Patients with Type 2 Diabetes Diabetes Care 2003 Aug;26(8):2370-7	<b>19</b>
<b>Chapter 3</b>	Effectiveness of Progressive Dose-escalation of Exenatide (Exendin-4) in Reducing Dose-limiting Side Effects in Subjects with Type 2 Diabetes Diabetes Metab Res Rev. 2004 Sep-Oct;20(5):411-7	<b>33</b>
<b>Chapter 4</b>	Pharmacokinetics and Pharmacodynamics of Exenatide Extended-release after Single- and Multiple-dosing Clin Pharmacokinet. 2011 Jan 1;50(1):65-74	<b>47</b>
<b>Chapter 5</b>	GLP-1 Based Therapies: Differential Effects on Fasting and Postprandial Glucose Diabetes, Obesity, Metabolism: Submitted for publication	<b>63</b>
<b>Chapter 6</b>	Clinical Relevance of Anti-exenatide Antibodies: Safety, Efficacy, and Cross-reactivity with Long-term Treatment Diabetes, Obesity, Metabolism: Submitted for publication	<b>83</b>
<b>Chapter 7</b>	General Discussion & Summary	<b>101</b>
	Affiliation of Co-authors	<b>111</b>
	List of Publications	<b>115</b>
	List of Abbreviations	<b>121</b>
	Acknowledgments (Dankwoord)	<b>125</b>
	Curriculum Vitae	<b>129</b>